Financial News · Live Terminal

Goldman Sachs Adjusts Pentair PT to $91 From $98, Maintains Neutral Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $81.68, Change: $-1.18, Percent Change: -1.42%

$PNR

Raymond James Adjusts Price Target on Fair Isaac to $1,750 From $2,010, Maintains Outperform Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1013.71, Change: $+3.21, Percent Change: +0.32%

Baird Adjusts Price Target on Fair Isaac to $1,549 From $1,547, Maintains Outperform Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Goldman Sachs Adjusts Price Target on Fair Isaac to $1,543 From $1,528, Maintains Buy Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Needham Adjusts Price Target on Fair Isaac to $1,650 From $1,975, Maintains Buy Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Baird Adjusts Price Target on Allegion Public to $165 From $190, Maintains Neutral Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $138.98, Change: $+1.12, Percent Change: +0.81%

JPMorgan Adjusts Price Target on Allegion Public to $170 From $180, Maintains Overweight Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $138.98, Change: $+1.12, Percent Change: +0.81%

$BIDU$DQ$IBN$INFY$IQ$KRKR$NIO$RDY$SE$SIMO$TLK$UXIN$WIT$ZLAB

Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Asian equities traded in the US as American depositary receipts were little changed Wednesday morning, edging 0.03% lower to 2,762.13 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by semiconductor company Silicon Motion Technology (SIMO) and video streaming service iQIYI (IQ), which climbed 30.4% and 5.9%, respectively. They were followed by used car marketplace Uxin (UXIN) and electric vehicle maker NIO (NIO), which advanced 2.7% and 1.7%, respectively.The decliners from North Asia were led by polysilicon manufacturer Daqo New Energy (DQ) and brand platform 36Kr (KRKR), which fell 9.6% and 6.9%, respectively. They were followed by biopharmaceutical company Zai Lab (ZLAB) and tech company Baidu (BIDU), which were down 5.3% and 3.9%, respectively.From South Asia, the only gainers were IT firm Infosys (INFY) and telecommunications operator Telekomunikasi Indonesia (TLK), which were up 0.6% and 0.2% respectively.The decliners from South Asia were led by tech conglomerate Sea (SE) and pharmaceutical company Dr. Reddy's Laboratories (RDY), which dropped 3.6% and 1.9%, respectively. They were followed by lender ICICI Bank (IBN) and IT firm Wipro (WIT), which lost 1.1% and 1% respectively.Price: $194.15, Change: $+44.97, Percent Change: +30.14%

Commodities55d ago

Weekly US Crude Inventories Drop by 6.2 Million Barrels, EIA Says

US crude stockpiles dropped by 6.2 million barrels to 459.5 mmbbls in the week ended April 24, the Energy Information Administration said in its weekly report on Wednesday.Crude inventories are now about 1% above the five-year average for this time of year, the EIA said.

Dr. Reddy's Laboratories Receives Health Canada Approval for Generic Semaglutide

Dr. Reddy's Laboratories (RDY) said Wednesday it received a Notice of Compliance from Health Canada to market its generic semaglutide injection.The regulatory clearance makes the pharmaceutical manufacturer the first company to obtain approval for the type 2 diabetes treatment in the country, the company said.The authorization covers the 2 mg and 4 mg pen dosages and was granted ahead of the agency's target review date, it said.Shares of the company were down 1.9% in Wednesday trading.Price: $13.77, Change: $-0.26, Percent Change: -1.89%

$RDY

Research55d ago

Research Alert: Stanley Black & Decker Prints Q1 Beat; Debt Finally Near Manageable Levels

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SWK delivered Q1 adjusted EPS of $0.80, above the $0.59 consensus, while revenues of $3.8B grew 3% Y/Y amid ongoing tariff pressures and volume declines. Adjusted gross margins compressed 20 bps to 30.2% on lower volumes, though segment performance was mixed with Tools & Outdoor margins down 50 bps to 8.3% while Engineered Fastening expanded 350 bps to 11.9%. The $1.6B CAM divestiture proceeds strengthened SWK's balance sheet through debt reduction, sharpening focus on core operations. Management raised its 2026 GAAP EPS guidance to $4.15-$5.35 reflecting the divestiture gain, while reaffirming adjusted EPS guidance of $4.90-$5.70. Tools & Outdoor (87% of sales) grew 2% with pricing gains (+4%) offsetting North American retail volume declines (-5%), while Engineered Fastening delivered 10% growth driven by aerospace and automotive demand. We expect margin improvements to resume as the company benefits from improved leverage positioning and moves past current headwinds.

$SWK

Research55d ago

Research Alert: Cgi Sees Deteriorating Bookings Performance, Misses Revenue Expectations

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CGI posted Mar-Q sales of CAD4.16B (+3% Y/Y), missing consensus (CAD4.24B), with constant currency growth decelerating to 1.6% from 3.4% in the prior quarter. Adjusted EPS of CAD2.27 (+7%) met expectations despite the sales miss, supported by 10 bps margin expansion to 16.6% with notable improvements in U.S. Commercial/State (+180 bps Y/Y) and Canada (+230 bps Y/Y). Segment revenue performance was mixed, with U.K. and Australia leading at +19% Y/Y while U.S. Federal continued its decline at -11% Y/Y amid ongoing spending cuts. Bookings deteriorated, with book-to-bill falling to 103.8% from 109.5% in the prior quarter and TTM declining to 108.4% from 110.4%; however, CGI's acquisition-supported CAD31.5B backlog still grew slightly and provides solid visibility, with CAD11.5B expected to convert over the next twelve months. We expect continued headwinds from U.S. Federal weakness and slower bookings momentum, though we hesitate to attribute the weakness to AI competition (contrary to IT Services bears).

$GIB.A

Gilead Sciences Says HIV Combo NDA Gets FDA Priority Review

Gilead Sciences (GILD) said Wednesday the US Food and Drug Administration accepted its new drug application for an investigational once-daily HIV treatment combining bictegravir and lenacapavir, granting priority review with a target action date of Aug. 27.The application is backed by Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed the regimen maintained virological suppression at 48 weeks and was generally well tolerated in adults with HIV, including those switching from multi-tablet regimens or Biktarvy, the company said.The bictegravir 75-milligram and lenacapavir 50-mg combination remains investigational and has not been approved globally, with its safety and efficacy yet to be fully established, the company said.Price: $128.49, Change: $-0.77, Percent Change: -0.60%

$GILD

Commodities55d ago

US Weekly Ethanol Production Dropped, EIA Says

US weekly ethanol production dropped slightly, according to the US Energy Information Administration report on Wednesday.For the week ending April 24, US ethanol production averaged 1.01 million barrels per day, below 1.04 nnb/d last week and 1.04 mmb/d a year ago.

Visa Expands Agentic Ready Program to Asia Pacific, Latin America

Visa (V) said Wednesday it has expanded its Agentic Ready program to clients in the Asia Pacific and Latin America regions to prepare the payment sector for AI agent-led commerce.The initiative allows issuing banks and payment partners to test agent-initiated payments in controlled, real-world environments and validate processes including card enrollment, tokenization, authentication and transaction authorization, the company said.Participants can also evaluate trust, security and control mechanisms and identify operational readiness gaps before agent-led transactions scale broadly, Visa said.Visa said the program was first launched with banks and issuing partners across Europe, including the UK.Shares of the company were up about 8.4% in Wednesday trading.Price: $338.35, Change: $+29.05, Percent Change: +9.39%

$V

Wells Fargo Adjusts Sherwin-Williams Price Target to $350 From $365, Maintains Equal Weight Rating

Sherwin-Williams (SHW) has an average rating of overweight and mean price target of $383.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $317.80, Change: $-6.47, Percent Change: -2.00%

$SHW

Barclays Adjusts Price Target on Allegion Public to $161 From $165, Maintains Equalweight Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $139.24, Change: $+1.38, Percent Change: +1.00%

Goldman Sachs Adjusts Price Target on Allegion Public to $176 From $187, Maintains Buy Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $139.24, Change: $+1.38, Percent Change: +1.00%